Skip to content
Medical Health Aged Care

EW Healthcare Partners Acquires Stake in Boiron Group, a Leader in Natural Medicine

EW Healthcare Partners 2 mins read

LONDON, UK / ACCESSWIRE / October 27, 2023 / EW Healthcare Partners announced that it has acquired a c. 25% minority stake in Boiron Developpement, an entity formed for the purposes of launching a tender offer for the Boiron Group, in partnership with the Boiron Family, at a c. €875 million enterprise value. As part of this transaction, the Boiron family has transferred its 70% stake in the Boiron Group to Boiron Developpement, together with the Boiron employee fund for c. 5% of the capital.

Boiron is a French pharmaceutical company focused on natural medicine, founded in 1932 by pharmacists Jean and Henri Boiron. The company is built around homeopathy and has spearheaded the industry's global development.

Boiron today is the global market leader in homeopathy and a leading global player in natural medicines, with 2022 revenues of €534M. The company offers a diversified portfolio of natural, innovative, science-based, and personalized pharmaceutical products. Over 50% of Boiron's sales are realized outside of France. Boiron benefits from an integrated value chain from registration to distribution, including in-house manufacturing, with the company currently present in 50 countries globally through 23 subsidiaries and 30 distributors. Boiron has also established a strong footprint in the U.S. with €120M in U.S. revenue, with a large portion of products sold through the e-commerce channel.

EW Healthcare Partners is excited to partner with the Boiron family to help further accelerate the company's growth, by expanding the company's offering into additional healthcare verticals and capitalising on the existing platform to launch additional products, in particular in the U.S.

About EW Healthcare Partners ("EW")

With over $2 billion of capital raised since 2014, EW Healthcare Partners seeks to make growth equity investments in fast-growing commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in the United States and in Europe. EW Healthcare Partners has a singular commitment to the healthcare industry and has been a long-term investor in numerous healthcare companies, ranging across sectors, stages and geographies. The team of senior investment professionals, operating partners and advisors is based in New York, London and Houston. https://www.ewhealthcare.com

Contact Information

Anne DeMaret
Investor Relations
ademaret@ewhealthcare.com
(281) 528-1956

SOURCE: EW Healthcare Partners

.


View source version on accesswire.com:
https://www.accesswire.com/797118/ew-healthcare-partners-acquires-stake-in-boiron-group-a-leader-in-natural-medicine

More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17
Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.